Effect of ibopamine on the progression of chronic renal failure.
Persistent changes in the slope of the reciprocal of serum creatinine concentration against time after medical intervention are likely to reflect the influence of therapy on progression of chronic renal failure. This observation allowed us to demonstrate the ability of ibopamine, a new orally active dopamine-related drug, to improve renal function or at least to slow its deterioration in 20 patients studied over a period of 6 months. We also noted that the therapeutic response to the drug varied considerably according to the nature of the underlying nephropathy, with maximal benefit being observed in nonglomerular diseases.
D000328:Adult; D003404:Creatinine / Q000097:blood; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use*; D004298:Dopamine / Q000031:analogs & derivatives*; D005260:Female; D005921:Glomerulonephritis / Q000150:complications; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009395:Nephritis, Interstitial / Q000150:complications; D007690:Polycystic Kidney Diseases / Q000150:complications; D011379:Prognosis
D004232:Diuretics; C023487:ibopamine; D003404:Creatinine; D003846:Deoxyepinephrine; D004298:Dopamine